Effect of Statins on Renal Function and Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
Effect of Statins on Renal Function and Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
复制标题
他汀类药物对常染色体显性多囊肾病肾功能和肾总体积的影响
DOI：
10.1159/000509087
复制
发表时间：
2020-07
期刊：
影响因子：
3.7
通讯作者：
Sheng-Qiang Yu
中科院分区：
文献类型：
--
作者：
Cheng Xue;Li-Ming Zhang;Chenchen Zhou;Chang-Lin Mei;Sheng-Qiang Yu
背景：常染色体显性多囊肾病（ADPKD）是最常见的遗传性肾病，很少有治疗来减缓肾脏进展。降脂药物（他汀类药物）对ADPKD进展的影响尚无定论。方法：我们通过检索PubMed、Embase、Web of Science和Cochrane数据库（截至2019年11月）进行了系统综述和荟萃分析。估计肾小球滤过率（eGFR）和总肾容量（TKV）的变化是主要结局。通过随机效应模型计算连续结果的平均差异（md）和95%置信区间（ci）。结果：纳入5项临床研究，648名受试者。与对照组相比，他汀类药物在eGFR的年变化（4项研究，MD = - 0.13 mL/min/m2, 95% CI: - 0.78至0.52,p = 0.70）和TKV的年变化（3项研究，MD = - 1.17%, 95% CI: - 3.40至1.05,p = 0.30）方面没有显示出显著的益处。然而，他汀类药物显著降低尿蛋白排泄量（- 0.10 g/天，95% CI: - 0.16至-0.03,p = 0.004）和血清低密度脂蛋白水平（- 0.34 mmol/L, 95% CI: - 0.58至- 0.10,p = 0.006）。结论：尽管有这些降血脂和蛋白尿的益处，他汀类药物对ADPKD进展的影响尚不确定。
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary nephropathy with few treatments to slow renal progression. The evidence on the effect of lipid-lowering agents (statins) on ADPKD progression remains inconclusive. Methods: We performed a systematic review and meta-analysis by searching the PubMed, Embase, Web of Science, and Cochrane databases (up to November 2019). Changes in estimated glomerular filtration rate (eGFR) and total kidney volume (TKV) were the primary outcomes. Mean differences (MDs) for continuous outcomes and 95% confidence intervals (CIs) were calculated by a random-effects model. Results: Five clinical studies with 648 participants were included. Statins did not show significant benefits in the yearly change in eGFR (4 studies, MD = −0.13 mL/min/m2, 95% CI: −0.78 to 0.52, p = 0.70) and the yearly change in TKV (3 studies, MD = −1.17%, 95% CI: −3.40 to 1.05, p = 0.30) compared with the control group. However, statins significantly decreased urinary protein excretion (−0.10 g/day, 95% CI: −0.16 to -0.03, p = 0.004) and serum low-density lipoprotein level (−0.34 mmol/L, 95% CI: −0.58 to −0.10, p = 0.006). Conclusion: Despite these proteinuria and lipid-lowering benefits, the effect of statins on ADPKD progression was uncertain.
登录
查看更多内容
影响因子：
2.3
作者：
Klawitter J;Zafar I;Klawitter J;Pennington AT;Klepacki J;Gitomer BY;Schrier RW;Christians U;Edelstein CL
通讯作者：
Edelstein CL
成人常染色体显性多囊肾病的抗高血压治疗：随机对照试验的网络荟萃分析
影响因子：
--
作者：
Xue C;Zhou C;Dai B;Yu S;Xu C;Mao Z;Ye C;Chen D;Zhao X;Wu J;Chen W;Mei C
通讯作者：
Mei C
影响因子：
3.7
作者：
C. Xue;Chen Zhou;Ming Wu;C. Mei
通讯作者：
C. Xue;Chen Zhou;Ming Wu;C. Mei
影响因子：
13.2
作者：
GILE, RD;COWLEY, BD;GRANTHAM, JJ
通讯作者：
GRANTHAM, JJ
DOI：
10.2215/cjn.08350813
发表时间：
2014-05-07
影响因子：
9.8
作者：
Cadnapaphornchai, Melissa A.;George, Diana M.;Schrier, Robert W.
通讯作者：
Schrier, Robert W.